Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

3.34
+0.09002.77%
Post-market: 3.340.00000.00%17:42 EDT
Volume:312.70K
Turnover:1.03M
Market Cap:154.65M
PE:-1.12
High:3.34
Open:3.20
Low:3.17
Close:3.25
Loading ...

Discover Fractyl Health And 2 More Promising Penny Stocks

Simply Wall St.
·
22 Apr

4DMT Announces New Employment Inducement Grants

GlobeNewswire
·
12 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire
·
27 Mar

4D Molecular Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
11 Mar

BRIEF-4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy

Reuters
·
10 Mar

4Dmt Announces First Patients Enrolled in 4Front-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet Amd

THOMSON REUTERS
·
10 Mar

4D Molecular Therapeutics Inc - 4Front-2 Trial Expected to Initiate in Q3 2025

THOMSON REUTERS
·
10 Mar

Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
05 Mar

4D Molecular price target lowered to $35 from $39 at RBC Capital

TipRanks
·
04 Mar

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating

MT Newswires Live
·
04 Mar

4D Molecular price target lowered to $28 from $30 at Chardan

TIPRANKS
·
04 Mar

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
04 Mar

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Mar

Promising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating

TIPRANKS
·
03 Mar

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alcon (ALC) and Cooper Co (COO)

TIPRANKS
·
03 Mar

4D Molecular Therapeutics Inc : RBC Cuts Target Price to $35 From $39

THOMSON REUTERS
·
03 Mar

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
02 Mar